Optibrium appoints Ian Smith as Chief Technology Officer

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian Smith as Chief Technology Officer (CTO), the latest in a number of senior-level hires for the Company. With over 25 years of biopharma experience, Ian will oversee the development of the Company’s technology portfolio and cloud services and guide the team’s growth to support the continued expansion of the Company’s global customer base. This latest hire marks a key milestone for Optibrium as it enters the next phase of commercial growth as a provider of innovative computational and AI drug discovery technologies.

As CTO, Ian will lead the Software Engineering, DevOps and Quality Assurance teams, driving the scale-up of the Company’s infrastructure and managing the expanding portfolio of products and development projects.

Ian joins Optibrium having previously served as Head of Technology and Delivery for an insurance technology start-up, Hx—part of the Howden Group—where he developed innovative data, analytics and digital application-focused strategies through cloud platform delivery, as well as defining a target operating model to implement the Group’s data transformation and growth objectives. Prior to this, Ian worked at Merck, Sharp and Dohme (MSD), holding positions including Director of Research and Development Analytics, Director of IT Productivity and Director of Scientific Modelling & Real-World Data. During his tenure as Director R&D Analytics, Ian led a team to define, develop and execute an 18-month strategy to build Merck’s next-generation machine learning and AI-driven analytics platform and data science capabilities to mature research and develop scientific insights.

I’m excited to join Optibrium at a time of significant growth and success as the Company’s technologies drive computer-aided drug discovery across the biotech industry. I look forward to working with a world-class team to develop our innovative platforms, further transforming customers’ drug discovery programmes.” 

Ian Smith, Chief Technology Officer, Optibrium

Edmund Champness, Chief Scientific Officer, Optibrium, said: “We are delighted to welcome Ian to the team to support the scale-up of our infrastructure and technical teams and to lead the development and deployment of our next-generation solutions. Ian brings an impressive combination of experience in cloud engineering, platform development and the pharma industry, which will be invaluable as we continue to expand our computational drug discovery platforms.”

For further information on Optibrium, please visit www.optibrium.com, contact [email protected] or call +44 1223 815900.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Optibrium Ltd.. (2022, November 23). Optibrium appoints Ian Smith as Chief Technology Officer. News-Medical. Retrieved on December 09, 2022 from https://www.news-medical.net/news/20221123/Optibrium-appoints-Ian-Smith-as-Chief-Technology-Officer.aspx.

  • MLA

    Optibrium Ltd.. "Optibrium appoints Ian Smith as Chief Technology Officer". News-Medical. 09 December 2022. <https://www.news-medical.net/news/20221123/Optibrium-appoints-Ian-Smith-as-Chief-Technology-Officer.aspx>.

  • Chicago

    Optibrium Ltd.. "Optibrium appoints Ian Smith as Chief Technology Officer". News-Medical. https://www.news-medical.net/news/20221123/Optibrium-appoints-Ian-Smith-as-Chief-Technology-Officer.aspx. (accessed December 09, 2022).

  • Harvard

    Optibrium Ltd.. 2022. Optibrium appoints Ian Smith as Chief Technology Officer. News-Medical, viewed 09 December 2022, https://www.news-medical.net/news/20221123/Optibrium-appoints-Ian-Smith-as-Chief-Technology-Officer.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Optibrium Raises Investment to Advance Computer-Aided Drug Discovery